Sarepta (NASDAQ:SRPT) made a 19% leap higher on Monday after the company's drug eteplirsen, which treats Duchenne muscular dystrophy, received more praise during a conference in London. In this video segment, Motley Fool health care analyst Brenton Flynn talks about what the company's focus will be from here forward, and how its potential competition in this space also helped the stock yesterday.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.